Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2023)

Historic EBIT Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' EBIT Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063875218800.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • As of Q4 2023, Inhibikase Therapeutics' EBIT Margin stood at 440356600.0%, which was down 4403497803600.0% from 5993.38% recorded in Q3 2023.
  • Inhibikase Therapeutics' 5-year EBIT Margin high stood at 186.56% for Q1 2021, and its period low was 440356600.0% during Q4 2023.
  • Its 4-year average for EBIT Margin is 27549298.5%, with a median of 5660.72% in 2023.
  • Per our database at Business Quant, Inhibikase Therapeutics' EBIT Margin skyrocketed by 2000000000bps in 2022 and then tumbled by 2000000000bps in 2023.
  • Inhibikase Therapeutics' EBIT Margin (Quarter) stood at 704.66% in 2020, then plummeted by -36703bps to 259334.41% in 2021, then skyrocketed by 97bps to 6819.64% in 2022, then crashed by -6457080bps to 440356600.0% in 2023.
  • Its last three reported values are 440356600.0% in Q4 2023, 5993.38% for Q3 2023, and 5328.07% during Q2 2023.